Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

CAP TODAY Roundtables

External controls critical to crucial assays

August 2025—CAP TODAY publisher Bob McGonnagle spoke on May 14 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Meghan Starolis, MS, PhD, HCLD(ABB), senior science director for infectious diseases at Quest Diagnostics, Chantilly, Va.

Jessica VanAllen
Dr. Van Allen
Dr. Starolis
Dr. Starolis

Read the article:

Bob McGonnagle: Jessica Van Allen, I’d like to talk about some of the hot topics in molecular infectious disease testing, and you mentioned in our discussions offline that viral load testing for transplant viruses is becoming ever more important in the field. Can you make a few remarks about that?

Jessica Van Allen, PhD (Zepto­Metrix): There’s testing that is done using laboratory-developed tests and testing performed using FDA-cleared assays. Those are the two big buckets of testing in the labs of our customers. Meghan and I attended a conference recently at which a couple of the speakers talked about viral load testing for common transplant viruses—EBV, CMV, VZV, some adenoviruses. We’ve been playing in that field for a long time in terms of molecular controls for viruses, so they’re products we’ve had on the shelf. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by ZeptoMetrix.

‘Stick to the basics’: service, quality, and cost

July 2025—What’s new from Roche, Hologic, and Siemens Healthineers, and how they aim to lighten for labs the burden of the workforce shortage. CAP TODAY publisher Bob McGonnagle spoke about these and other things with three company representatives in an online roundtable, and Stan Schofield, Compass Group managing principal, told them what three questions companies must answer to get a laboratory’s business. Their June 2 conversation follows.

Focus on instruments: scalability, timelines, and IT

June 2025—Chemistry and immunoassay analyzers—the customer input that shapes their development and the laboratory acquisition process and timeline. That and more, including the IT obstacles and solutions, were the focus of a roundtable, led by CAP TODAY publisher Bob McGonnagle. He spoke with Moira Larsen, MD, MBA, of MedStar Health; Joe Baker of Baylor Scott & White; and representatives of Beckman Coulter, Roche, and Siemens Healthineers. Read about their April 15 online conversation.

NGS and the cancer biomarker balancing act

May 2025—In-house or send out, small panel or large, ease of use, getting the most information possible from a sample and doing it fast—that was at the center of a March 17 conversation on next-generation sequencing, led by CAP TODAY publisher Bob McGonnagle. “More and more patients need this testing faster and faster,” Jeremy Segal, MD, PhD, of the University of Chicago, said. What he and four industry executives told us in the online roundtable follows.

Unraveling, reducing payer denials—billing experts talk

April 2025—Payer policy changes—“It’s almost impossible for the provider community to keep up,” Harley Ross of XiFin said in a Feb. 14 online roundtable led by CAP TODAY publisher Bob McGonnagle. Ross and five other experts in pathology and laboratory medicine billing talked about prior authorizations, denials, narrow networks, and the need to advocate for laboratories.

One angle on cancer care

April 2025—CAP TODAY publisher Bob McGonnagle spoke with Anthony Alburo, MBA, market development manager, diagnostics, Tosoh Bioscience, Melanie Samko, director of marketing, Tosoh Bioscience, and Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare. Anthony Alburo opens the conversation.

Read the article:

Anthony Alburo: Tosoh Bioscience has a longstanding legacy in immunoassay diagnostics and HPLC [high-performance liquid chromatography] technology. Our immunoassay platforms support comprehensive cancer care with reimbursable tests for oncology, endocrinology, reproductive health, and chronic disease management. Our HPLC column solution has set the standard in A1C testing, a key factor in managing diabetes, which can intersect with cancer treatment. We remain committed to advancing laboratory science to support clinicians and patients at every stage of care.

I’m honored to introduce Melanie Samko, our director of marketing, who brings not only a deep expertise in health care marketing but also a deep personal perspective: She is a breast cancer survivor. Her journey highlights the real-world impact of early detection, diagnostic accuracy, and patient advocacy. Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare, which recently merged with the US Oncology Network, has extensive expertise in laboratory operations and compliance. She will provide invaluable insights into the challenges and advancements in oncology diagnostics. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by Tosoh Bioscience in recognition of National Cancer Prevention Month.

On value, preanalytics, and personnel in urinalysis

March 2025—Urinalysis reflex rules, reimbursement, instruments, research, and specimen handling and transport are some of what came up in the Jan. 15 roundtable with eight participants online and CAP TODAY publisher Bob McGonnagle leading the discussion.

Views on digital pathology, AI, and the AP LIS

February 2025—Digital pathology, artificial intelligence, and anatomic pathology computer systems—seven participants in a Dec. 10, 2024 online roundtable talked with CAP TODAY publisher Bob McGonnagle about their experiences, plans, and predictions. Large academic center practices and small pathology practices—they considered all perspectives. Here is what they told us.

Should grade group 1 prostate cancer be renamed?

January 2025—Whether grade group 1 prostate cancer should be renamed to “noncancer” was the center of debate on a CAP podcast last fall led by Gladell P. Paner, MD, in discussion with Ming Zhou, MD, PhD, and Rajal B. Shah, MD. Dr. Paner is professor of pathology and surgery, University of Chicago Pritzker School of Medicine, and director of the genitourinary pathology service and of the reproductive endocrinology and infertility laboratory, UChicago Medicine.

Coagulation automation, from workflow to middleware

Automation in coagulation was the topic of a Nov. 11, 2024 roundtable led by CAP TODAY publisher Bob McGonnagle. Put it on a line or on a dedicated automation platform? Seven participants talked about that and about cybersecurity, viscoelastic testing, and the labor shortage, among other things.

MARKETPLACE

TRENDING